Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
Kang Wang(Hebei North University), Theodoros Foukakis(Karolinska Institutet), Thomas Hatschek(Karolinska University Hospital), Ingrid Hedenfalk(Lund University), Yizhe Sun(Center for Life Sciences), Dhifaf Sarhan(Karolinska Institutet), Dimitris C. Kanellis(Science for Life Laboratory), Alexios Matikas(Karolinska University Hospital), Artur Mezheyeuski(Uppsala University), Janne Lehtiö(Karolinska University Hospital), Jonas Bergh(Karolinska Institutet), Ioannis Zerdes(Karolinska University Hospital), Henrik J. Johansson, Jiří Bártek(Science for Life Laboratory), Xingrong Liu(Karolinska Institutet), Niklas Loman(Lund University), Emmanouil G. Sifakis(Karolinska Institutet)
Cited by 24
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k